Pacific Edge slashes team on US 'uncertainty'

Pacific Edge slashes team on US 'uncertainty'
(Image: PEB)
Brent Melville
Pacific Edge has halved its sales team after uncertainty over its future in its core US market, with a pending decision on whether medicare contractor Novitas will cover US testing.  The cancer diagnostic company, dual listed on the New Zealand and Australian stock exchanges, slashed its commercial team from 34 to 17 as it restructured its operations after a 17.78% drop in test volumes for its Cxbladder product in its core US market for the December quarter.The Dunedin firm said it had processed 7,172 tests during the final three months of...

More Markets

Warehouse drops guidance, loss now in scope
Retail

Warehouse drops guidance, loss now in scope

The retailer has raised the possibility of a full-year earnings loss.

Xero’s Melio ‘leap of faith’
Markets Analysis

Xero’s Melio ‘leap of faith’

The NZ-founded company’s giant-killer dreams in the US hinge on this huge bet. 

NZX ends half year down 3.6%
Markets Market Close

NZX ends half year down 3.6%

"We’ve continued to lag relative to other markets," analyst says.

Gregor Thompson 30 Jun 2025